替莫唑胺治疗复发性胶质瘤的疗效分析

晏 怡; 唐文渊; 邓朝霞

doi:10.3971/j.issn.1000-8578.2010.01.025

替莫唑胺治疗复发性胶质瘤的疗效分析

1. 400016 重庆医科大学附属第一医院神经外科；2.第三军医大学西南医院急救部

详细信息

中图分类号: R730.264；R730.53
计量
- 文章访问数: 2354
- HTML全文浏览量: 17
- PDF下载量: 555
出版历程
- 收稿日期: 2008-09-15
- 修回日期: 2009-03-11
- 刊出日期: 2010-02-24

Efficacy of Temozolomide in Treatment of Recurrent Glioma

1.Department of Neurosurgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016,China;2.Department of Intensive Care Unit, Xi'nan Hospital of The Third Military Medical University

摘要

摘要: 目的观察并评价替莫唑胺对复发性胶质瘤的临床疗效。方法 35例复发性胶质瘤患者，14例首次使用替莫唑胺治疗（F组），10例再次或多次使用替莫唑胺治疗（R组），11例从未使用（N组），定期临床随访、分析所有纳入病例的治疗反应。结果疗效评价指标包括完全缓解(complete response，CR)，部分缓解(partial response，PR)，稳定(stable disease，SD)，进展(progressive disease，PD)及肿瘤进展时间（time of tumor progression, TTP），半年肿瘤无进展数比和半年生存数比。其中F组的PR+SD较R组与N组高且差异有统计学意义（P<0.05），F组的半年生存例数比为13/15，显著高于R组的5/10（P<0.05）和N组的4/11（P<0.01）。结论替莫唑胺化疗对初次用药的复发性胶质瘤有效，但对再次使用替莫唑胺治疗组中的病例疗效不明显。
- 复发性胶质瘤 /
- 化疗 /
- 替莫唑胺
Abstract: Objective To evaluate the efficacy of Temozolomide in the treatment of recurrent glioma. Methods Thirty-five patients with recurrent glioma were enrolled in our study. According to the history of temozolomide administration, 35 patients were divided into group F (the patients first treated with temozolomide), group R (the patients re-treated with temozolomide), and group N (the patients without chemotherapeutic history). Clinical evaluations and assessments of tumor response were performed every 2 months. Results In group F, the complete response(CR) was not observed, partial response (PR) in 6 cases, stable disease(SD)in 10 cases, and 5 cases developed progressive disease(PD). In group R, the complete response(CR) was not observed, partial response (PR) was observed in 2 cases, stable disease(SD)in 4 cases, and 9 cases developed progressive disease(PD). In group N, the complete response(CR) was not observed, partial response (PR) was observed in 1 cases, stable disease(SD)in 5 cases, and 9 cases developed progressive disease(PD). Therein, (PR+SD) in group F was significantly higher than group R and group N respectively (both P<0.05). Cases of 6 month overall survival in group F was more than those in group R (P<0.05) and group N (P<0.01). Conclusion Initial use of temozolomide is effective for recurrent glioma, but the curative effectiveness of temozolomide re-administration is not obvious.
- recurrent malignant glioma /
- chemotherapy /
- temozolomide.